Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial.

Buist DS, LaCroix AZ, Black DM, Harris F, Blank J, Ensrud K, Edgerton D, Rubin S, Fox KM.

J Am Geriatr Soc. 2000 Sep;48(9):1126-31.

PMID:
10983914
2.

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D.

Arch Intern Med. 2000 Feb 28;160(4):517-25.

PMID:
10695692
3.

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial.

Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, Black D, Suryawanshi S, Hochberg M, Yates J; FIT Research Group.

J Am Geriatr Soc. 2002 Mar;50(3):409-15.

PMID:
11943033
4.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
5.

Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT).

Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y, Cummings SR, Nevitt MC.

Osteoporos Int. 2003 Jan;14(1):69-76.

PMID:
12577187
6.

Randomized placebo-controlled trial of brisk walking in the prevention of postmenopausal osteoporosis.

Ebrahim S, Thompson PW, Baskaran V, Evans K.

Age Ageing. 1997 Jul;26(4):253-60.

PMID:
9271287
7.

Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial.

LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE.

Ann Intern Med. 2000 Oct 3;133(7):516-26.

PMID:
11015164
8.

Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.

Clin Ther. 2004 Feb;26(2):245-56.

PMID:
15038947
9.

Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.

Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA.

Arch Intern Med. 2004 Jan 26;164(2):146-52.

PMID:
14744837
10.

The clinical tolerability profile of alendronate.

Watts N, Freedholm D, Daifotis A.

Int J Clin Pract Suppl. 1999 Apr;101:51-61. Review.

PMID:
12669741
11.

Persistence with weekly alendronate therapy among postmenopausal women.

Lo JC, Pressman AR, Omar MA, Ettinger B.

Osteoporos Int. 2006;17(6):922-8. Epub 2006 Apr 12.

PMID:
16609824
12.

Predictors of participation in an HIV risk reduction intervention for socially deprived Latino women: a cross sectional cohort study.

Kim YJ, Peragallo N, DeForge B.

Int J Nurs Stud. 2006 Jul;43(5):527-34. Epub 2005 Sep 8.

PMID:
16153646
13.

Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.

Lufkin EG, Sarkar S, Kulkarni PM, Ciaccia AV, Siddhanti S, Stock J, Plouffe L Jr.

Curr Med Res Opin. 2004 Mar;20(3):351-7. Review.

PMID:
15025844
14.

Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.

Blotman F, Cortet B, Hilliquin P, Avouac B, Allaert FA, Pouchain D, Gaudin AF, Cotté FE, El Hasnaoui A.

Drugs Aging. 2007;24(7):603-14.

PMID:
17658910
15.

Distal radius fractures in older women: a 10-year follow-up study of descriptive characteristics and risk factors. The study of osteoporotic fractures.

Vogt MT, Cauley JA, Tomaino MM, Stone K, Williams JR, Herndon JH.

J Am Geriatr Soc. 2002 Jan;50(1):97-103.

PMID:
12028253
16.

Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.

Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr.

J Am Geriatr Soc. 2004 Sep;52(9):1543-8.

PMID:
15341559
17.

Low bone mineral density and fracture burden in postmenopausal women.

Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD.

CMAJ. 2007 Sep 11;177(6):575-80.

18.

Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study.

Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA, Felsenberg D, Finn JD, Nuti R, Hoszowski K, Lorenc R, Miazgowski T, Jajic I, Lyritis G, Masaryk P, Naves-Diaz M, Poor G, Reid DM, Scheidt-Nave C, Stepan JJ, Todd CJ, Weber K, Woolf AD, Roy DK, Lunt M, Pye SR, O'neill TW, Silman AJ, Reeve J.

Bone. 2005 Mar;36(3):387-98.

PMID:
15777673

Supplemental Content

Support Center